Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
28/08/2026 02:31
BRIEF-Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech Aug 28 (Reuters) - Duality Biotherapeutics Inc 9606.HK:
GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH
GENENTECH TO OBTAIN EXCLUSIVE WORLDWIDE LICENSE TO COLLABORATION ANTIBODY-DRUG CONJUGATES
DUALITYBIO-B TO RECEIVE UPFRONT PAYMENT OF US$45 MILLION UNDER COLLABORATION AGREEMENT
Further company coverage: 9606.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Duality Biotherapeutics
See all newsDuality Biotherapeutics rises most in near six weeks on Roche's Genentech tie-up
Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
Brief: Duality Biotherapeutics Obtains Acceptance From Shanghai Securities Regulatory Bureau For Counselling On Proposed RMB Share Listing
Brief: Duality Biotherapeutics Announces Share Repurchase Plan Of Up To $40 Million
Brief: Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board